A CANADIAN RETROSPECTIVE CHART REVIEW EVALUATING CONCOMITANT METHOTREXATE DE-ESCALATION PATTERNS IN RA PATIENTS TREATED WITH BIOLOGIC OR TARGETED SYNTHETIC DMARDS

被引：1
|
作者：
Bessette, L. [1 ]
Florica, B. [2 ]
Fournier, P. A. [3 ]
Girard, T. [3 ]
Naik, L. [4 ]
Sholter, D. [5 ]
Baer, P. [6 ]
机构：
[1] Univ Laval, Fac Med, Dept Med, Laval, PQ, Canada
[2] Univ Toronto, Dept Internal Med, Toronto, ON, Canada
[3] AbbVie Corp, Med Affairs, St Laurent, PQ, Canada
[4] Univ Saskatchewan, Dept Adult Rheumatol, Saskatoon, SK, Canada
[5] Univ Alberta, Dept Med, Edmonton, AB, Canada
[6] Baer Weinberg MPC, Med, Scarborough, ON, Canada
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2022年 / 81卷
关键词：
D O I：
10.1136/annrheumdis-2022-eular.1286
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
POS0288
引用
收藏
页码：388 / 389
页数：2
相关论文
共 6 条
  • [1] A Canadian Retrospective Chart Review Evaluating Concomitant Methotrexate De- escalation Patterns in RA Patients Treated With Biologic or Targeted Synthetic DMARDs
    Bessette, Louis
    Florica, Brandusa
    Fournier, Pierre-Andre
    Girard, Tanya
    Naik, Latha
    Sholter, Dalton
    Baer, Philip
    [J]. JOURNAL OF RHEUMATOLOGY, 2023, 50 (07) : 52 - 52
  • [2] A Canadian Retrospective Chart Review Evaluating Concomitant Methotrexate De-escalation Patterns in Patients with Rheumatoid Arthritis Treated with Biologic or Targeted Synthetic DMARDs
    Bessette, Louis
    Florica, Brandusa
    Naik, Latha
    Sholter, Dalton
    Fournier, Pierre-Andre
    Girard, Tanya
    Liazoghli, Dalinda
    Baer, Philip A.
    [J]. RHEUMATOLOGY AND THERAPY, 2024, 11 (05) : 1165 - 1180
  • [3] Is There Any Difference in RA Patients for Methotrexate Use Vs. Leflunomide Use As a Concomitant Treatment with Biological and Targeted Synthetic Dmards in Turkbio Registry?
    Inanc, Nevsun
    Ozen, Gulsen
    Yalcinkaya, Yasemin
    Dalkilic, Ediz
    Koca, Suleyman Serdar
    Can, Gercek
    Karatas, Ahmet
    Pehlivan, Yavuz
    Yazici, Ayten
    Cefle, Ayse
    Tufan, Abdurrahman
    Akar, Servet
    Senel, Soner
    Oz, Burak
    Akkoc, Nurullah
    Onen, Fatos
    [J]. ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [4] IS THERE ANY DIFFERENCE IN RA PATIENTS FOR METHOTREXATE USE VS. LEFLUNOMIDE USE AS A CONCOMITANT TREATMENT WITH BIOLOGICAL AND TARGETED SYNTHETIC DMARDS IN TURKBIO REGISTRY?
    Inanc, N.
    Ozen, G.
    Yalcinkaya, Y.
    Dalkilic, E.
    Koca, S. S.
    Can, G.
    Karatas, A.
    Pehlivan, Y.
    Yazici, A.
    Cefle, A.
    Tufan, A.
    Akar, S.
    Senel, S.
    Oz, B.
    Akkoc, N.
    Onen, F.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 611 - 612
  • [5] DRUG RETENTION OF BIOLOGIC AND TARGETED SYNTHETIC DMARDS IN KOREAN SEROPOSITIVE RHEUMATOID ARTHRITIS (RA) PATIENTS: A REALWORLD SINGLE-CENTER RETROSPECTIVE STUDY
    Lee, B. W.
    Lee, J. J.
    Kim, W. U.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 730 - 731
  • [6] Reasons for Early Discontinuation of Targeted Synthetic (ts) or Biologic (b) DMARDs; Chart Review of 20,343 Drug Episodes Given to Patients with Rheumatoid Arthritis
    Huston, Kent Kwas
    Adams, Christopher
    Helfgott, Simon
    Singh, Jasvinder
    Soloman, Nehad
    Persons, Dan
    Milligan, Scott
    Edgerton, Colin
    [J]. ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 498 - 501
1